Bristol Myers Squibb disclosed that a confirmatory study for Krazati failed in colorectal cancer, detailing the setback in what the company characterized as part of ongoing evidence generation for the program. The report follows a period of attention on how Krazati’s broader development plan performs in confirmatory settings. The development centers on patients receiving Krazati in combination with another therapy, alongside the EGFR inhibitor component described in BMS’ update. While the precise efficacy and statistical outcomes were not fully included in the excerpt, the disclosure underscores how confirmatory trials remain a key gate for maintaining or expanding regulatory and commercial momentum. For biotech strategy, the event reinforces the importance of durability in tumor context and trial design as oncology drugs move beyond initial signals toward registration-grade proof.